---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-016060"
form_type: "8-K"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:42:46.123726+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tevogen Bio expects to eliminate $94.9M liabilities via note conversion; launches AI initiative, appoints new leaders

## Summary
- Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.
- Pro forma balance sheet shows no remaining convertible note liabilities; $80.7M current and $14.2M long-term removed.
- Operating expenses for Tevogen Bio Inc. in 2023 were $8.8M, primarily non-cash charges from note fair value changes.
- Launches Tevogen.ai AI initiative to enhance drug discovery, manufacturing, and patient access; Mittul Mehta appointed CIO.
- Appoints Tapan V. Shah as Head of Investor Relations and Corporate Development; 25-year Wall Street veteran.

## SEC filing metadata
- accession: 0001493152-24-016060
- form_type: 8-K
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315224016060/0001493152-24-016060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315224016060/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-016060
- JSON: https://secwatch.observer/filing/0001493152-24-016060.json
- Plain text: https://secwatch.observer/filing/0001493152-24-016060.txt

## Key facts
- Earnings Releases
  Tevogen Bio Holdings Inc. reported preliminary financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: preliminary results
  source text: On April 26, 2024, Tevogen Bio Holdings Inc. (the “Company”) issued a press release announcing certain expected pro forma combined financial results of the Company and the Company’s wholly owned subsidiary, Tevogen Bio Inc. (“Tevogen Bio”), and certain expected financial results of Tevogen Bio as of and for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860871/000149315224016060/0001493152-24-016060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.